MIPLYFFA
Growtharimoclomol citrate
NDAORALCAPSULEPriority Review
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIPLYFFA (arimoclomol citrate) is an oral small-molecule heat shock protein co-inducer approved in September 2024. The drug is indicated for treating motor neuron diseases, working by enhancing cellular stress response pathways to protect neuronal function. It represents a novel mechanistic approach to neurodegenerative disease management.
Growth15.0 years to LOE
Early commercial phase with minimal competitive pressure; brand team will focus on market penetration, healthcare provider education, and patient access infrastructure expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Early-stage approved asset with minimal linked positions suggests selective hiring focused on medical expertise and safety oversight. Significant career opportunity exists in building the Medical Affairs infrastructure from ground up, establishing clinical narratives, and managing pharmacovigilance as real-world data accumulates.
Medical Director (U.S. Medical Affairs)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.